These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35893842)

  • 1. Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus.
    Figueiredo TH; Aroniadou-Anderjaska V; Pidoplichko VI; Apland JP; Braga MFM
    Toxics; 2022 Jul; 10(8):. PubMed ID: 35893842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing Long-Term Brain Damage by Nerve Agent-Induced Status Epilepticus in Rat Models Applicable to Infants: Significant Neuroprotection by Tezampanel Combined with Caramiphen but Not by Midazolam Treatment.
    De Araujo Furtado M; Aroniadou-Anderjaska V; Figueiredo TH; Pidoplichko VI; Apland JP; Rossetti K; Braga MFM
    J Pharmacol Exp Ther; 2024 Jan; 388(2):432-450. PubMed ID: 37739807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electroencephalographic analysis in soman-exposed 21-day-old rats and the effects of midazolam or LY293558 with caramiphen.
    De Araujo Furtado M; Aroniadou-Anderjaska V; Figueiredo TH; Apland JP; Braga MFM
    Ann N Y Acad Sci; 2020 Nov; 1479(1):122-133. PubMed ID: 32237259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the glutamatergic system to counteract organophosphate poisoning: A novel therapeutic strategy.
    Aroniadou-Anderjaska V; Figueiredo TH; Apland JP; Braga MF
    Neurobiol Dis; 2020 Jan; 133():104406. PubMed ID: 30798006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed tezampanel and caramiphen treatment but not midazolam protects against long-term neuropathology after soman exposure.
    Figueiredo TH; Aroniadou-Anderjaska V; Apland JP; Rossetti K; Braga MF
    Exp Biol Med (Maywood); 2023 Apr; 248(7):612-623. PubMed ID: 37300407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the Antiseizure and Neuroprotective Efficacy of LY293558, Diazepam, Caramiphen, and LY293558-Caramiphen Combination against Soman in a Rat Model Relevant to the Pediatric Population.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Pidoplichko VI; Rossetti K; Braga MFM
    J Pharmacol Exp Ther; 2018 May; 365(2):314-326. PubMed ID: 29467308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; De Araujo Furtado M; Braga MFM
    Neurotox Res; 2018 Oct; 34(3):511-524. PubMed ID: 29713995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Prager EM; Olsen CH; Braga MFM
    Neurotox Res; 2017 Nov; 32(4):694-706. PubMed ID: 28776308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
    Figueiredo TH; Qashu F; Apland JP; Aroniadou-Anderjaska V; Souza AP; Braga MF
    J Pharmacol Exp Ther; 2011 Feb; 336(2):303-12. PubMed ID: 20962029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY293558 prevents soman-induced pathophysiological alterations in the basolateral amygdala and the development of anxiety.
    Prager EM; Figueiredo TH; Long RP; Aroniadou-Anderjaska V; Apland JP; Braga MF
    Neuropharmacology; 2015 Feb; 89():11-8. PubMed ID: 25204221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.
    Miller SL; Aroniadou-Anderjaska V; Figueiredo TH; Prager EM; Almeida-Suhett CP; Apland JP; Braga MF
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):204-16. PubMed ID: 25689173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Green CE; Swezey R; Yang C; Qashu F; Braga MF
    J Pharmacol Exp Ther; 2013 Jan; 344(1):133-40. PubMed ID: 23042954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The K
    Barker BS; Spampanato J; McCarren HS; Berger K; Jackson CE; Yeung DT; Dudek FE; McDonough JH
    Neuroscience; 2021 May; 463():143-158. PubMed ID: 33836243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The limitations of diazepam as a treatment for nerve agent-induced seizures and neuropathology in rats: comparison with UBP302.
    Apland JP; Aroniadou-Anderjaska V; Figueiredo TH; Rossetti F; Miller SL; Braga MF
    J Pharmacol Exp Ther; 2014 Nov; 351(2):359-72. PubMed ID: 25157087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylcholinesterase inhibitors (nerve agents) as weapons of mass destruction: History, mechanisms of action, and medical countermeasures.
    Aroniadou-Anderjaska V; Apland JP; Figueiredo TH; De Araujo Furtado M; Braga MF
    Neuropharmacology; 2020 Dec; 181():108298. PubMed ID: 32898558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.
    White HS; Alex AB; Pollock A; Hen N; Shekh-Ahmad T; Wilcox KS; McDonough JH; Stables JP; Kaufmann D; Yagen B; Bialer M
    Epilepsia; 2012 Jan; 53(1):134-46. PubMed ID: 22150444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The recovery of acetylcholinesterase activity and the progression of neuropathological and pathophysiological alterations in the rat basolateral amygdala after soman-induced status epilepticus: relation to anxiety-like behavior.
    Prager EM; Aroniadou-Anderjaska V; Almeida-Suhett CP; Figueiredo TH; Apland JP; Rossetti F; Olsen CH; Braga MF
    Neuropharmacology; 2014 Jun; 81():64-74. PubMed ID: 24486384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiseizure and neuroprotective effects of delayed treatment with midazolam in a rodent model of organophosphate exposure.
    Spampanato J; Pouliot W; Bealer SL; Roach B; Dudek FE
    Epilepsia; 2019 Jul; 60(7):1387-1398. PubMed ID: 31125451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Lacosamide and Rufinamide as Adjuncts to Midazolam-Ketamine Treatment Against Cholinergic-Induced Status Epilepticus in Rats.
    Lumley LA; Nguyen DA; de Araujo Furtado M; Niquet J; Linz EO; Schultz CR; Stone MF; Wasterlain CG
    J Pharmacol Exp Ther; 2024 Jan; 388(2):347-357. PubMed ID: 37977809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure.
    Rossetti F; de Araujo Furtado M; Pak T; Bailey K; Shields M; Chanda S; Addis M; Robertson BD; Moffett M; Lumley LA; Yourick DL
    Neurotoxicology; 2012 Jun; 33(3):500-11. PubMed ID: 22387230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.